NeoTract Receives Phoenix 2016 Most Promising New Product Award for UroLift® Device for Enlarged Prostate

Guía de Regalos

PLEASANTON, Calif.–(BUSINESS WIRE)–NeoTract, Inc., a medical device company focused on addressing unmet
needs in urology, today announced that the company’s UroLift®
System received the Phoenix 2016 Most Promising New Product Award at the
23rd Annual Phoenix Conference in Laguna Beach, Calif. The UroLift
System was recognized for its novel and much less invasive approach for
alleviating symptoms caused by benign prostatic hyperplasia (BPH), also
known as an enlarged prostate.

“It is very gratifying to be recognized by the Phoenix Conference
organizers and conference attendees, leaders who have developed many
breakthroughs that have revolutionized the treatment of a wide variety
of conditions,” said Dave Amerson, president and CEO of NeoTract.
“UroLift’s selection as the most promising new product from an
impressive field of innovations is exciting. We are pleased that our
peers recognize the system’s benefits for physicians and for the
millions of men who suffer from BPH.”

“The original vision for the UroLift device was to develop an innovative
solution for BPH that involved no cutting, heating or removal of tissue,
in a simple and intuitive procedure,” said Ted Lamson, Ph.D., founder
and Chief Technical Officer of NeoTract. “Bringing the device from
concept to fruition has been incredibly rewarding, and is the result of
commitment and dedication of the NeoTract team and many collaborative
physicians who share our vision for new, better solutions for BPH.”

The Phoenix Awards are presented for outstanding achievement in the
medical device and diagnostic industry to individuals and companies
selected by industry CEOs. Past recipients of the Most Promising New
Product Award include Johnson and Johnson (cardiac stent, drug eluting
stent), Guidant (implantable defibrillator), St. Jude Medical
(Nanostim), Acclarent (balloon sinuplasty), Neuronetics (NeuroStar TMS
Therapy System), CardioMEMS (wireless heart failure management system),
and Concentric Medical (clot removal device for stroke).

The UroLift System is a first-line treatment that gets men off BPH
medications and allows them to avoid major surgery, while preserving
sexual function. Long-term clinical data from the LIFT randomized study
published in Urologic
Clinics of North America
showed that, after four years, patients
treated with the UroLift device continue to experience symptom relief
with minimal side effects, with few patients requiring an additional
procedure for relief.1 A second randomized clinical trial
called BPH6 demonstrated that the minimally invasive UroLift device
compares very well to the reference standard surgery, transurethral
resection of the prostate (TURP), with regard to efficacy, and is
superior to TURP at preserving sexual function and offering a more rapid
recovery.2

Symptoms of BPH often include sleepless nights and urinary problems, and
can cause loss of productivity, depression and decreased quality of
life. Medication is often the first-line therapy for enlarged prostate,
but relief can be inadequate and temporary. Side effects of medication
treatment can include sexual dysfunction, dizziness and headaches,
prompting many patients to quit using the drugs. For these patients, the
classic alternative is surgery that cuts, heats or removes prostate
tissue to open the blocked urethra. While current surgical options can
be very effective in relieving symptoms, they can also leave patients
with permanent side effects such as urinary incontinence, erectile
dysfunction and retrograde ejaculation (dry orgasm).

About the Phoenix Conference

Phoenix: The Medical Device and Diagnostic Conference for Chief
Executive Officers began in 1994. The conference was developed to
provide CEOs in the medical device and diagnostic industries with an
opportunity to meet with peers and explore issues critical to the
success of their companies and industries.

About the UroLift System

The FDA-cleared UroLift System is a novel, minimally invasive technology
for treating lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH). The UroLift permanent implants, delivered during a
minimally invasive transurethral outpatient procedure, relieve prostate
obstruction and open the urethra directly without cutting, heating, or
removing prostate tissue. Clinical data from a pivotal 206-patient
randomized controlled study showed that patients with enlarged prostate
receiving UroLift implants reported rapid and durable symptomatic and
urinary flow rate improvement without compromising sexual function.
Patients also experienced a significant improvement in quality of life.
Most common adverse events reported include hematuria, dysuria,
micturition urgency, pelvic pain, and urge incontinence. Most symptoms
were mild to moderate in severity and resolved within two to four weeks
after the procedure. The UroLift System is available in the U.S.,
Europe, Australia and Canada. Learn more at www.UroLift.com.

About NeoTract

NeoTract, Inc. is dedicated to developing innovative, minimally invasive
and clinically effective devices that address unmet needs in the field
of urology. The company’s initial focus is on improving the standard of
care for patients with BPH using the UroLift System, a minimally
invasive permanent implant system that treats symptoms while preserving
normal sexual function. Learn more at www.NeoTract.com.

1 Roehrborn Urology Clinics 2016
2 Sonksen et
al J Urology 2016

Contacts

for NeoTract, Inc.
Nicole Osmer, 650-454-0505
nicole@nicoleosmer.com